These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30923187)

  • 1. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Humbert M; Farber HW; Ghofrani HA; Benza RL; Busse D; Meier C; Hoeper MM
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30923187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.
    Benza RL; Farber HW; Frost A; Grünig E; Hoeper MM; Busse D; Meier C; Nikkho S; Ghofrani HA
    J Heart Lung Transplant; 2018 Jul; 37(7):836-843. PubMed ID: 29580746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
    Garnock-Jones KP
    Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
    McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
    BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
    Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
    Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.
    Benza RL; Farber HW; Frost A; Ghofrani HA; Gómez-Sánchez MA; Langleben D; Rosenkranz S; Busse D; Meier C; Nikkho S; Hoeper MM
    J Heart Lung Transplant; 2018 Apr; 37(4):513-519. PubMed ID: 29223470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study.
    Benza RL; Boucly A; Farber HW; Frost AE; Ghofrani HA; Hoeper MM; Lambelet M; Rahner C; Bansilal S; Nikkho S; Meier C; Sitbon O
    J Heart Lung Transplant; 2022 Mar; 41(3):411-420. PubMed ID: 34848133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Benza RL; Ghofrani HA; Grünig E; Hoeper MM; Jansa P; Jing ZC; Kim NH; Langleben D; Simonneau G; Wang C; Busse D; Meier C; Ghio S
    J Heart Lung Transplant; 2021 Oct; 40(10):1172-1180. PubMed ID: 34353714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of off-label targeted drugs on long-term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry.
    Xia W; Qian Y; Lin Y; Quan R; Yang Y; Yang Z; Tian H; Li S; Shen J; Ji Y; Gu Q; Han H; Xiong C; He J
    Respirology; 2024 Jul; 29(7):614-623. PubMed ID: 38494833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
    Benza RL; Simonneau G; Ghofrani HA; Corris PA; Langleben D; Rosenkranz S; White RJ; Cheng CC; Campos FTAF; Kim HK; Souza R; Chang M; Rahner C; Meier C; Hoeper MM
    J Heart Lung Transplant; 2024 Oct; 43(10):1756-1760. PubMed ID: 38852934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
    Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M; Clarke MM; Pogue KT
    J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the REVEAL risk score calculator 2.0 in the CHEST study.
    Benza RL; Farber HW; Frost AE; Ghofrani HA; Corris PA; Lambelet M; Nikkho S; Meier C; Hoeper MM
    Respir Med; 2022; 195():106783. PubMed ID: 35256218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA
    Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
    Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
    Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.